European Cancer Congress 2015: The Role of PD-1 Therapeutics in the Management of Patients with Metastatic Melanoma

30 Day Survey

Since completing this CME activity, to what extent do you believe it has helped you: *

Please use the scale: 1=Much less, 2=Less, 3=The same amount, 4=More, 5=Much more, N/A=Not applicable to me

	1	2	3	4	5	NA
Review the recently released data for PD-1 therapies in the treatment of melanoma	Review the recently released data for PD-1 therapies in the treatment of melanoma - 1	Review the recently released data for PD-1 therapies in the treatment of melanoma - 2	Review the recently released data for PD-1 therapies in the treatment of melanoma - 3	Review the recently released data for PD-1 therapies in the treatment of melanoma - 4	Review the recently released data for PD-1 therapies in the treatment of melanoma - 5	Review the recently released data for PD-1 therapies in the treatment of melanoma - NA
Analyze the strategies to apply novel PD-1 specific treatments to the care of patients with melanoma	Analyze the strategies to apply novel PD-1 specific treatments to the care of patients with melanoma - 1	Analyze the strategies to apply novel PD-1 specific treatments to the care of patients with melanoma - 2	Analyze the strategies to apply novel PD-1 specific treatments to the care of patients with melanoma - 3	Analyze the strategies to apply novel PD-1 specific treatments to the care of patients with melanoma - 4	Analyze the strategies to apply novel PD-1 specific treatments to the care of patients with melanoma - 5	Analyze the strategies to apply novel PD-1 specific treatments to the care of patients with melanoma - NA

Since completing this CME activity, how often have you been using each of the following strategies with respect to the diagnosis and management of patients with metastatic melanoma? *

Please use the scale: 1=Much less, 2=Less, 3=The same amount, 4=More, 5=Much more, N/A=Not applicable to me

	1	2	3	4	5	NA
Address patient-specific disease progression and develop individualized treatment plans for your metastatic melanoma patients based on newly introduced immunotherapies.	Address patient-specific disease progression and develop individualized treatment plans for your metastatic melanoma patients based on newly introduced immunotherapies. - 1	Address patient-specific disease progression and develop individualized treatment plans for your metastatic melanoma patients based on newly introduced immunotherapies. - 2	Address patient-specific disease progression and develop individualized treatment plans for your metastatic melanoma patients based on newly introduced immunotherapies. - 3	Address patient-specific disease progression and develop individualized treatment plans for your metastatic melanoma patients based on newly introduced immunotherapies. - 4	Address patient-specific disease progression and develop individualized treatment plans for your metastatic melanoma patients based on newly introduced immunotherapies. - 5	Address patient-specific disease progression and develop individualized treatment plans for your metastatic melanoma patients based on newly introduced immunotherapies. - NA
Utilize current science and clinical trial data to develop a strategy for applying novel PD-1 specific treatment options to a heterogenic patient population to improve long term survival rates.	Utilize current science and clinical trial data to develop a strategy for applying novel PD-1 specific treatment options to a heterogenic patient population to improve long term survival rates. - 1	Utilize current science and clinical trial data to develop a strategy for applying novel PD-1 specific treatment options to a heterogenic patient population to improve long term survival rates. - 2	Utilize current science and clinical trial data to develop a strategy for applying novel PD-1 specific treatment options to a heterogenic patient population to improve long term survival rates. - 3	Utilize current science and clinical trial data to develop a strategy for applying novel PD-1 specific treatment options to a heterogenic patient population to improve long term survival rates. - 4	Utilize current science and clinical trial data to develop a strategy for applying novel PD-1 specific treatment options to a heterogenic patient population to improve long term survival rates. - 5	Utilize current science and clinical trial data to develop a strategy for applying novel PD-1 specific treatment options to a heterogenic patient population to improve long term survival rates. - NA

Leave this field blank

Elsevier CME

European Cancer Congress 2015: The Role of PD-1 Therapeutics in the Management of Patients with Metastatic Melanoma

30 Day Survey

Pre-Activity Questions

Course Video

Post-Activity Test

Evaluation

30 Day Survey

You are here

European Cancer Congress 2015: The Role of PD-1 Therapeutics in the Management of Patients with Metastatic Melanoma

30 Day Survey

Pre-Activity Questions

Course Video

Post-Activity Test

Evaluation

30 Day Survey